Compugen Gears Up to Report Q3 Earnings: Here's What to Expect

Zacks10-25

We expect investors to focus on Compugen Ltd.’s CGEN progress with the development of its portfolio of pipeline candidates for various oncology indications, when it reports third-quarter 2024 earnings...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2478682986?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","is_english":true,"pubTime":"2024-10-25 00:12","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2478682986","market":"us","top_or_hot":-1,"title":"Compugen Gears Up to Report Q3 Earnings: Here's What to Expect","media":"Zacks","content":"<div>\n<p>We expect investors to focus on Compugen Ltd.’s CGEN progress with the development of its portfolio of pipeline candidates for various oncology indications, when it reports third-quarter 2024 earnings...</p>\n\n<a href=\"https://finance.yahoo.com/news/compugen-gears-report-q3-earnings-161200227.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compugen Gears Up to Report Q3 Earnings: Here's What to Expect</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompugen Gears Up to Report Q3 Earnings: Here's What to Expect\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-25 00:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/compugen-gears-report-q3-earnings-161200227.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We expect investors to focus on Compugen Ltd.’s CGEN progress with the development of its portfolio of pipeline candidates for various oncology indications, when it reports third-quarter 2024 earnings...</p>\n\n<a href=\"https://finance.yahoo.com/news/compugen-gears-report-q3-earnings-161200227.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGEN","symbol_name":"Compugen医疗","start_time":0,"source_url":"https://finance.yahoo.com/news/compugen-gears-report-q3-earnings-161200227.html","article_id":"2478682986","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478682986","pubTimestamp":1729786320,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We expect investors to focus on Compugen Ltd.’s CGEN progress with the development of its portfolio of pipeline candidates for various oncology indications, when it reports third-quarter 2024 earnings.Let’s see how things have shaped up for the quarter to be reported.Compugen’s top line currently comprises revenues recognized from its license agreement with Gilead Sciences GILD and AstraZeneca. The company reported $6.7 million in revenues in the last reported quarter, comprising an upfront payment from GILD and a milestone payment from AstraZeneca.The IND clearance triggered a $30 million milestone payment for Compugen from Gilead, which is expected to be recorded as revenues in the third quarter. The company plans to begin the phase I study on COM503 in solid tumors later in the fourth quarter of 2024. We expect management to provide more updates on the same during the third-quarter earnings call.Our proven model does not conclusively predict an earnings beat for Compugen this time a","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CGEN":"Compugen医疗"},"translate_title":"Compugen准备报告第三季度收益：以下是预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEN":1},"content_text":"We expect investors to focus on Compugen Ltd.’s CGEN progress with the development of its portfolio of pipeline candidates for various oncology indications, when it reports third-quarter 2024 earnings.\nLet’s see how things have shaped up for the quarter to be reported.\nFactors to Note\nCompugen’s top line currently comprises revenues recognized from its license agreement with Gilead Sciences GILD and AstraZeneca. The company reported $6.7 million in revenues in the last reported quarter, comprising an upfront payment from GILD and a milestone payment from AstraZeneca.\nIn July, the FDA cleared CGEN’s investigational new drug (IND) application seeking to initiate a phase I study on its high affinity anti-IL-18 binding protein antibody, COM503, for the treatment of solid tumors. COM503 has been licensed to GILD.\nThe IND clearance triggered a $30 million milestone payment for Compugen from Gilead, which is expected to be recorded as revenues in the third quarter. The company plans to begin the phase I study on COM503 in solid tumors later in the fourth quarter of 2024. We expect management to provide more updates on the same during the third-quarter earnings call.\nCompugen’s two proprietary product candidates, COM701 and COM902, are currently in phase I development for the treatment of solid tumors. The company is currently evaluating the triple combination of COM701 plus COM902 plus Merck’s blockbuster PD-1 inhibitor, Keytruda (pembrolizumab), in a proof-of-concept study for treating patients with platinum-resistant ovarian cancer. Data from the same is expected to be presented later in the fourth quarter of 2024.\nCompugen’s partner AstraZeneca is developing rilvegostomig, a PD-1/TIGIT bi-specific derived from COM902, which is currently in phase III development for various cancer indications. Its successful development and a potential approval for rilvegostomig will make Compugen eligible for future milestones and mid-single-digit tiered royalty payments from AstraZeneca.\nOperating expenses declined in the last reported quarter. It remains to be seen whether the same trend continued in the third quarter or not.\nShares of Compugen have plunged 14.6% so far this year compared with the industry’s decrease of 2.5%.\nImage Source: Zacks Investment Research\nCGEN's Earnings Surprise History\nCompugen has a mixed earnings surprise history. The company’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion. CGEN delivered an average surprise of 20.70%. In the last reported quarter, Compugen’s earnings beat estimates by 75.00%.\n\nCompugen Ltd. Price and EPS Surprise\n  \nCompugen Ltd. price-eps-surprise | Compugen Ltd. Quote\n\nFind the latest EPS estimates and surprises on Zacks Earnings Calendar.\nEarnings Whispers for CGEN Stock\nOur proven model does not conclusively predict an earnings beat for Compugen this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.\nEarnings ESP: Compugen has an Earnings ESP of 0.00% as the Most Accurate Estimate and the Zacks Consensus Estimate are both pegged at 21 cents per share.\nZacks Rank: Compugen currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.\nStocks to Consider\nHere are some stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.\nExelixis, Inc. EXEL has an Earnings ESP of +15.66% and a Zacks Rank #2 at present.\nShares of EXEL have gained 18.1% in the year-to-date period. Earnings of EXEL beat estimates in two of the trailing four quarters and missed the same twice, delivering an average surprise of 13.25%. EXEL will report third-quarter results on Oct. 31.\nBiogen BIIB has an Earnings ESP of +1.97% and a Zacks Rank #3.\nBiogen’s stock has lost 29.3% year to date. BIIB beat earnings estimates in three of the last four quarters while missing on the remaining occasion. On average, Biogen delivered an earnings surprise of 10.25% in the last four quarters. BIIB will report third-quarter results on Oct. 30.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBiogen Inc. (BIIB) : Free Stock Analysis Report\nGilead Sciences, Inc. (GILD) : Free Stock Analysis Report\nExelixis, Inc. (EXEL) : Free Stock Analysis Report\nCompugen Ltd. (CGEN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478682986"}